V-set and immunoglobulin domain containing 8Genealiases: []
Q-omics provides the consensus-scored VSIG8 profile across patient tissues and cancer cell-line models. VSIG8 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, VSIG8 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, VSIG8 RNA expression shows 16,454 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THCA, KIRC, and UVM as cancer lineages where VSIG8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VSIG8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VSIG8 survival associations across molecular data types. VSIG8 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VSIG8 RNA expression–survival associations across cancer types. High VSIG8 expression shows unfavorable associations in THCA, BRCA, LGG, MESO, BLCA and KIRC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for VSIG8 RNA expression.
This table summarizes VSIG8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for VSIG8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VSIG8 shows lower tumor expression in KIRC, KIRP, THCA, HNSC and KICH and higher tumor expression in COAD. The KIRC box plot shows higher VSIG8 RNA expression in normal versus tumor tissue (log2 FC = −1.748, t-test p < 0.001).
This table shows molecular features associated with VSIG8 in patient tissues and cancer cell lines. In patient samples, VSIG8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, VSIG8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SOFT_TISSUE.
